Lesley Seymour

Dr. Lesley Seymour is a Professor in the Department of Oncology at Queen's University and serves as Director of the Investigational New Drug Program at the Canadian Cancer Trials Group (CCTG). Her research focuses on cancer clinical trials and therapeutic drug development, with particular expertise in biomarker-driven approaches and precision oncology. She leads initiatives such as the PC_BETS platform study, which integrates ctDNA analysis for treatment selection in prostate cancer. Dr. Seymour has contributed to guidelines on early phase trial design (SPIRIT-DEFINE/CONSORT-DEFINE) and has advanced understanding of drug resistance mechanisms, including CDK4/6 inhibitor-resistant breast cancer. Her work spans immunotherapy, targeted therapies, and global cooperative trials, emphasizing patient-centric methodologies. Notably, she co-led the phase III trial of pembrolizumab in malignant pleural mesothelioma, demonstrating improved outcomes with combination therapy.

• Key Roles: Director, Investigational New Drug Program (CCTG); Professor, Department of Oncology (Queen's University)
• Research Themes: Liquid biopsy applications, biomarker development, clinical trial innovation